Evidence map›Paper›PMID 36793800›Full record

ArticleFrontiers in neurology2022

Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach.

Jinnie Ko, Hannah Furby, Xiaoye Ma, Jeffrey D Long, Xiao-Yu Lu, Diana Slowiejko, Rita Gandhy

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01574053 (Enroll -HD), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01574053 recruitingnot on this map

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Typeobservational_patient_registrySponsorCHDI Foundation, Inc.Ran2012 to 2062Enrolled35,000ConditionsHuntington's Disease
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Goal-directedness deficit in Huntington's disease.Cognitive, affective & behavioral neuroscience · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Jinnie KoGenentech Inc., South San Francisco, CA, United States.
Hannah FurbyRoche Products Ltd., Welwyn Garden City, United Kingdom.
Xiaoye MaGenentech Inc., South San Francisco, CA, United States.
Jeffrey D LongUniversity of Iowa Health Care, Iowa City, IA, United States.
Xiao-Yu LuGenentech Inc., South San Francisco, CA, United States.
Diana SlowiejkoGenentech Inc., South San Francisco, CA, United States.
Rita GandhyGenentech Inc., South San Francisco, CA, United States.
Roche (United Kingdom) · GBUniversity of Iowa Health Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Huntington's disease (HD) is a rare neurodegenerative disease characterized by cognitive, behavioral and motor symptoms that progressively worsen with time. Cognitive and behavioral signs of HD are generally present in the years prior to a diagnosis; however, manifest HD is typically assessed by genetic confirmation and/or the presence of unequivocal motor symptoms. Nevertheless, there is a large variation in symptom severity and rate of progression among individuals with HD. Methods: In this retrospective study, longitudinal natural history of disease progression was modeled in individuals with manifest HD from the global, observational Enroll-HD study (NCT01574053). Unsupervised machine learning (k-means; km3d) was used to jointly model clinical and functional disease measures simultaneously over time, based on one-dimensional clustering concordance such that individuals with manifest HD ( Results: The cytosine adenine guanine-age product score (a product of age and polyglutamine repeat length) at enrollment was the top predicting feature for cluster assignment, followed by years since symptom onset, medical history of apathy, body mass index at enrollment and age at enrollment. Conclusions: These results are useful for understanding factors that affect the global rate of decline in HD. Further work is needed to develop prognostic models of HD progression as these could help clinicians with individualized clinical care planning and disease management.

Indexed as

clusteringHuntington's diseasemachine learningpredictiontrajectory

Identifiers

PMID36793800
PMCPMC9923354
OpenAlexW4318475187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.